"FDA Approves Next-Generation Balloon For AF Treatment"
CardioFocus, announced the approval of its next-generation balloon designed for the treatment of paroxysmal AF. The balloon (HeartLight Excalibur Balloon) is expected to be fully launched in the United States in late 2018, according to a press release from the company. It was launched in Europe in September. "We have seen encouraging results with the Excalibur Balloon. It obtains an impressive antral position and establishes even more tissue contact, which enables contiguous lesion sets," said Vivek Reddy, MD, MS, professor of medicine and cardiology at the Icahn School of Medicine at Mount Sinai and director of cardiac arrhythmia services for the Mount Sinai Health System. "This is a clear advance in the field of balloon-based AF ablation, delivering on the promise of an ultra-compliant balloon."
- Vivek Reddy, MD, MS, Professor, Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, Director, Cardiac Arrhythmia Services, Mount Sinai Health System